Oregon Public Employees Retirement Fund Increases Holdings in Regeneron Pharmaceuticals Inc (REGN)

Oregon Public Employees Retirement Fund raised its holdings in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 47.9% in the 1st quarter, Holdings Channel reports. The firm owned 26,027 shares of the biopharmaceutical company’s stock after buying an additional 8,434 shares during the period. Oregon Public Employees Retirement Fund’s holdings in Regeneron Pharmaceuticals were worth $10,687,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in REGN. Smithfield Trust Co. bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $27,000. Whittier Trust Co. increased its position in shares of Regeneron Pharmaceuticals by 195.7% in the fourth quarter. Whittier Trust Co. now owns 68 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 45 shares during the period. Harel Insurance Investments & Financial Services Ltd. bought a new position in shares of Regeneron Pharmaceuticals in the first quarter worth $29,000. AdvisorNet Financial Inc increased its position in shares of Regeneron Pharmaceuticals by 208.0% in the fourth quarter. AdvisorNet Financial Inc now owns 77 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 52 shares during the period. Finally, Captrust Financial Advisors bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth $30,000. 67.63% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Neil Stahl sold 9,853 shares of Regeneron Pharmaceuticals stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the sale, the executive vice president now directly owns 47,450 shares of the company’s stock, valued at $14,507,363. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total value of $305,930.00. Following the sale, the director now directly owns 11,323 shares in the company, valued at $3,464,045.39. The disclosure for this sale can be found here. Insiders have sold 141,968 shares of company stock worth $57,360,056 over the last three months. Insiders own 11.84% of the company’s stock.

A number of research analysts recently commented on REGN shares. Cantor Fitzgerald restated a “hold” rating and issued a $441.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, February 6th. BidaskClub cut Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, April 25th. Oppenheimer raised their price target on Regeneron Pharmaceuticals from $440.00 to $480.00 and gave the stock an “outperform” rating in a research report on Thursday, February 7th. Jefferies Financial Group decreased their price target on Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating on the stock in a research report on Wednesday, April 17th. Finally, Canaccord Genuity restated a “hold” rating and issued a $353.00 price target (down previously from $408.00) on shares of Regeneron Pharmaceuticals in a research report on Wednesday, May 8th. Three equities research analysts have rated the stock with a sell rating, eleven have issued a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $404.88.

NASDAQ:REGN traded down $3.10 during trading hours on Friday, hitting $304.94. The company’s stock had a trading volume of 755,535 shares, compared to its average volume of 898,115. The firm has a market capitalization of $33.66 billion, a PE ratio of 15.40, a price-to-earnings-growth ratio of 1.45 and a beta of 1.08. The company has a quick ratio of 3.78, a current ratio of 4.58 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals Inc has a twelve month low of $291.10 and a twelve month high of $442.00.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $4.45 earnings per share for the quarter, missing the consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The business had revenue of $1.71 billion during the quarter, compared to analyst estimates of $1.76 billion. During the same period last year, the business earned $4.67 earnings per share. The business’s quarterly revenue was up 13.3% compared to the same quarter last year. On average, analysts anticipate that Regeneron Pharmaceuticals Inc will post 18.37 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Oregon Public Employees Retirement Fund Increases Holdings in Regeneron Pharmaceuticals Inc (REGN)” was originally posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://sportsperspectives.com/2019/05/18/oregon-public-employees-retirement-fund-increases-holdings-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Featured Article: Understanding Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.